Testing the application of new chemical formulations for neurological disease therapies
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.6/9788 |
Resumo: | Parkinson’s Disease (PD) is a multifactorial neurodegenerative disease, characterised by a decrease in the dopamine levels released by the dopaminergic neurons, the formation of Lewis bodies, formed mainly by a-synuclein and by the death of dopaminergic neurons of the substantia nigra. Several different mechanisms are dysregulated in Parkinson’s disease such as the inflammatory process; the dysfunction of mitochondria; the synthesis and degradation of dopamine and the activation of NADPH oxidases, all resulting in the production of reactive oxygen species (ROS) in large quantity which originates a highly oxidative environment in the dopaminergic neurons. Given the high importance of oxidative stress in Parkinson’s Disease, it is of particular interest the use of antioxidants in the treatment of this disease, such as vanillic acid, syringic acid and salicylic acid. However, these compounds present low solubility and low bioavailability which makes impracticable their use in the treatment of Parkinson’s Disease. Thus, in this thesis, new formulations of cholinium-based ionic liquids were used in order to increase the solubility and therefore the bioavailability od these compounds. For each ILs based antioxidant and its respective precursor, cytotoxicity and neuroprotection tests were performed in the dopaminergic neurons cell line (N27). The obtained results disclosed that vanillic acid, syringic acid, salicylic acid, cholinium vanillate, cholinium syringate and cholinium salicylate do not present cytotoxicity to dopaminergic neurons. Furthermore, it was also possible to conclude that none of the tested compounds (precursors and respective ionic liquids) exhibited neuroprotective characteristics in the three different in vitro models of PD tested. |
id |
RCAP_e5656c3acf8896bb6a5d1a02fc703c59 |
---|---|
oai_identifier_str |
oai:ubibliorum.ubi.pt:10400.6/9788 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Testing the application of new chemical formulations for neurological disease therapiesAntioxidantesDoença de ParkinsonLíquidos IónicosNeurónios DopaminérgicosStress OxidativoDomínio/Área Científica::Ciências Naturais::Ciências QuímicasParkinson’s Disease (PD) is a multifactorial neurodegenerative disease, characterised by a decrease in the dopamine levels released by the dopaminergic neurons, the formation of Lewis bodies, formed mainly by a-synuclein and by the death of dopaminergic neurons of the substantia nigra. Several different mechanisms are dysregulated in Parkinson’s disease such as the inflammatory process; the dysfunction of mitochondria; the synthesis and degradation of dopamine and the activation of NADPH oxidases, all resulting in the production of reactive oxygen species (ROS) in large quantity which originates a highly oxidative environment in the dopaminergic neurons. Given the high importance of oxidative stress in Parkinson’s Disease, it is of particular interest the use of antioxidants in the treatment of this disease, such as vanillic acid, syringic acid and salicylic acid. However, these compounds present low solubility and low bioavailability which makes impracticable their use in the treatment of Parkinson’s Disease. Thus, in this thesis, new formulations of cholinium-based ionic liquids were used in order to increase the solubility and therefore the bioavailability od these compounds. For each ILs based antioxidant and its respective precursor, cytotoxicity and neuroprotection tests were performed in the dopaminergic neurons cell line (N27). The obtained results disclosed that vanillic acid, syringic acid, salicylic acid, cholinium vanillate, cholinium syringate and cholinium salicylate do not present cytotoxicity to dopaminergic neurons. Furthermore, it was also possible to conclude that none of the tested compounds (precursors and respective ionic liquids) exhibited neuroprotective characteristics in the three different in vitro models of PD tested.A doença de Parkinson é uma doença neurodegenerativa multifatorial, caracterizada pela diminuição dos níveis de dopamina libertados pelos neurónios dopaminérgicos, pela formação dos corpos de Lewis, constituídos maioritariamente por a-sinucleína e pela morte dos neurónios dopaminérgicos da substantia nigra. Diferentes mecanismos estão desregulados na Doença de Parkinson tais como o processo inflamatório que resulta na microgliose e astrogliose, disfunção da mitocôndria, síntese e degradação da dopamina e ativação da NADPH oxidase, que culima na produção de espécies reativas de oxigénio em grande quantidade criando um ambiente oxidativo nos neurónios dopaminérgicos. Dado a grande importância do stress oxidativo nesta patologia, é do maior interesse a utilização de antioxidantes no seu tratamento, como por exemplo o ácido vanílico, o ácido siríngico e o ácido salicílico. Contudo estes compostos apresentam baixa solubilidade e baixa biodisponibilidade o que dificulta a sua utilização no tratamento da Doença de Parkinson. Desta forma, na presente tese foram utilizadas formulações de Líquidos Iónicos derivados de colina que aumentam a solubilidade e biodisponibilidade dos antioxidantes. Para cada uma das formulações e respetivo precursor foram realizados ensaios em neurónios dopaminérgicos (linha celular N27) para determinar a sua citotoxicidade e o potencial neuroprotector. Dos resultados obtidos foi possível concluir que o ácido vanílico, o ácido siríngico, o ácido salicílico, a colina vanilato, a colina siringato e a colina salicilato não apresentam citotoxicidade para os neurónios dopaminérgicos. Foi ainda concluído que nenhum dos compostos testados (precursores e líquidos iónicos) apresentam potencial de neuroprotecção nos três modelos in vitro de doença de Parkinson.Cristóvão, Ana Clara BrazSousa, Ana CatarinaFreire, Mara G.uBibliorumDavid, Emanuel Silva2018-10-82018-11-052024-09-06T00:00:00Z2018-11-05T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.6/9788TID:202348814enginfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-15T09:51:05Zoai:ubibliorum.ubi.pt:10400.6/9788Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:49:52.102793Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Testing the application of new chemical formulations for neurological disease therapies |
title |
Testing the application of new chemical formulations for neurological disease therapies |
spellingShingle |
Testing the application of new chemical formulations for neurological disease therapies David, Emanuel Silva Antioxidantes Doença de Parkinson Líquidos Iónicos Neurónios Dopaminérgicos Stress Oxidativo Domínio/Área Científica::Ciências Naturais::Ciências Químicas |
title_short |
Testing the application of new chemical formulations for neurological disease therapies |
title_full |
Testing the application of new chemical formulations for neurological disease therapies |
title_fullStr |
Testing the application of new chemical formulations for neurological disease therapies |
title_full_unstemmed |
Testing the application of new chemical formulations for neurological disease therapies |
title_sort |
Testing the application of new chemical formulations for neurological disease therapies |
author |
David, Emanuel Silva |
author_facet |
David, Emanuel Silva |
author_role |
author |
dc.contributor.none.fl_str_mv |
Cristóvão, Ana Clara Braz Sousa, Ana Catarina Freire, Mara G. uBibliorum |
dc.contributor.author.fl_str_mv |
David, Emanuel Silva |
dc.subject.por.fl_str_mv |
Antioxidantes Doença de Parkinson Líquidos Iónicos Neurónios Dopaminérgicos Stress Oxidativo Domínio/Área Científica::Ciências Naturais::Ciências Químicas |
topic |
Antioxidantes Doença de Parkinson Líquidos Iónicos Neurónios Dopaminérgicos Stress Oxidativo Domínio/Área Científica::Ciências Naturais::Ciências Químicas |
description |
Parkinson’s Disease (PD) is a multifactorial neurodegenerative disease, characterised by a decrease in the dopamine levels released by the dopaminergic neurons, the formation of Lewis bodies, formed mainly by a-synuclein and by the death of dopaminergic neurons of the substantia nigra. Several different mechanisms are dysregulated in Parkinson’s disease such as the inflammatory process; the dysfunction of mitochondria; the synthesis and degradation of dopamine and the activation of NADPH oxidases, all resulting in the production of reactive oxygen species (ROS) in large quantity which originates a highly oxidative environment in the dopaminergic neurons. Given the high importance of oxidative stress in Parkinson’s Disease, it is of particular interest the use of antioxidants in the treatment of this disease, such as vanillic acid, syringic acid and salicylic acid. However, these compounds present low solubility and low bioavailability which makes impracticable their use in the treatment of Parkinson’s Disease. Thus, in this thesis, new formulations of cholinium-based ionic liquids were used in order to increase the solubility and therefore the bioavailability od these compounds. For each ILs based antioxidant and its respective precursor, cytotoxicity and neuroprotection tests were performed in the dopaminergic neurons cell line (N27). The obtained results disclosed that vanillic acid, syringic acid, salicylic acid, cholinium vanillate, cholinium syringate and cholinium salicylate do not present cytotoxicity to dopaminergic neurons. Furthermore, it was also possible to conclude that none of the tested compounds (precursors and respective ionic liquids) exhibited neuroprotective characteristics in the three different in vitro models of PD tested. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-10-8 2018-11-05 2018-11-05T00:00:00Z 2024-09-06T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.6/9788 TID:202348814 |
url |
http://hdl.handle.net/10400.6/9788 |
identifier_str_mv |
TID:202348814 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799136389750587392 |